Intermittent Fasting for Crohn's Disease
Trial Summary
What is the purpose of this trial?
The purpose of this study is to see how an Intermittent Calorie Reduced Diet (IRCD) that mimics fasting (also known as a fasting mimicking diet, FMD) effects inflammation in patients with mild to moderate Crohn's disease (CD). The diet may allow users to receive the benefits of fasting while also being able to enjoy food (the ingredients of which are GRAS (generally recognized as safe) by the Food and Drug Administration (FDA). Research on dietary interventions and CD are very limited. Diets that mimick fasting have been studied with support of the National Institute of Health and published in leading journals. This research investigates whether markers of inflammation decrease and/or quality of life increases after five-day periods of the IRCD, and may provide rationale for its use to treat CD.
Research Team
Sidhartha R Sinha, MD
Principal Investigator
Stanford University
Eligibility Criteria
Adults aged 18-70 with mild to moderate Crohn's disease can join this trial. It's not for those allergic to nuts, severely weakened by illness or medical procedures, with severe heart issues, pregnant/nursing women, or anyone on a calorie-restricted diet. People who've had certain gastrointestinal surgeries or have serious conditions like diabetes at risk of hypoglycemia are also excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo three cycles of a 5-day Intermittent Reduced Calorie Diet (IRCD) administered once a month, followed by a regular diet for the rest of the month
Follow-up
Participants are monitored for changes in quality of life, clinical response, and inflammatory markers after the treatment phase
Treatment Details
Interventions
- Intermittent Reduced Calorie Diet (IRCD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor